2025. Impact of Amlitelimab (An Anti-OX40 Ligand Antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results From the 52-Week STREAM-AD Phase 2b Study. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s604. DOI:https://doi.org/10.25251/2ddr5090.